Brian Adams
General Counsel at RELAY THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-04-29
Profile
Brian R.
Adams is currently the Secretary & Chief Legal Officer at Relay Therapeutics, Inc. He previously worked as the Secretary, Senior Vice President & General Counsel at Keryx Biopharmaceuticals, Inc. from 2014 to 2018, and as the General Counsel at Algeta ASA from 2012 to 2014.
Mr. Adams completed his undergraduate degree at Harvard University and his graduate degree at Columbus School of Law.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
RELAY THERAPEUTICS, INC.
0.25% | 2024-04-28 | 325,767 ( 0.25% ) | 2 M $ | 2024-04-29 |
Brian Adams active positions
| Companies | Position | Start |
|---|---|---|
| RELAY THERAPEUTICS, INC. | General Counsel | 2018-02-28 |
Former positions of Brian Adams
| Companies | Position | End |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | General Counsel | 2018-03-12 |
| ALGETA ASA | General Counsel | 2014-02-28 |
Training of Brian Adams
| Harvard University | Undergraduate Degree |
| Columbus School of Law | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| RELAY THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Brian Adams
